Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Coadministration with tenofovir disoproxil fumarate is not recommended below estimated CrCl 70 mL/min. Limits and monitoring The threshold applies to the combination with tenofovir DF. Confirm the tenofovir product and monitor kidney function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted May 26, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Source-integrity finding: verify the product and source. Atenolol mirror mixes an IV heading with oral instructions Use a matched oral or IV label for the prescribed route. The mixed mirror was excluded from this release.
These are dated source observations, not claims that the publisher has corrected the page. Other correctly scoped evidence remains available.
Renal measure CrCl normalized to 1.73 m2, mL/min/1.73 m2 Renal action or finding For oral atenolol, the label caps the daily dose at 50 mg when indexed CrCl is 15-35 mL/min/1.73 m2 and at 25 mg below 15. Some patients with hypertension need a 25 mg initial dose. Limits and monitoring The HD instruction is a separate, supervised postdialysis regimen because marked hypotension can occur. This source addresses oral tablets. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted May 01, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild or moderate renal impairment had no clinically meaningful effect on atezolizumab exposure in the cited analysis. Limits and monitoring Confirm the route. The intravenous product and the subcutaneous combination with hyaluronidase have different administration instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 46, posted Oct 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild or moderate renal impairment had no clinically meaningful effect on atezolizumab exposure in the cited analysis. Limits and monitoring Confirm the route. The intravenous product and the subcutaneous combination with hyaluronidase have different administration instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 9, posted Oct 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding The effect of Cockcroft-Gault CrCl below 30 mL/min, including hemodialysis, on avatrombopag disposition is unknown. Limits and monitoring Select the indicated regimen and monitor platelets. No renal adjustment can be derived from this evidence gap. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 21, posted Aug 15, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding In the population analysis, Cockcroft-Gault CrCl 15-89 mL/min had no clinically meaningful effect on the antibody's pharmacokinetics. Limits and monitoring The analysis does not establish a dialysis dose. Review the product-specific toxicity precautions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 25, posted Sep 25, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild through severe renal impairment and ESRD do not require adjustment of azilsartan medoxomil. Creatinine elevations were more frequent with moderate or severe impairment. Limits and monitoring Monitor renal function and review volume depletion and concomitant renin-angiotensin system blockers. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 17, posted Jan 31, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding The azilsartan/chlorthalidone combination requires no renal adjustment at eGFR 30-90 mL/min/1.73 m2. Safety and efficacy below 30 remain unestablished. Limits and monitoring Monitor kidney function, volume and electrolytes. Review concomitant aliskiren restrictions separately. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 18, posted Nov 15, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding Adults with COVID-19 receive 2 mg daily at eGFR 30 to below 60 and 1 mg daily at 15 to below 30. Use is not recommended below 15, with ESRD or dialysis, or in acute kidney injury. Limits and monitoring RA and alopecia areata use different renal rules. Neither indication uses the COVID-19 severe-impairment regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 32, posted Oct 22, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The label specifies no renal dose reduction for belimumab. Limits and monitoring Confirm the indication and IV or subcutaneous presentation before selecting the regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 38, posted Sep 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure MDRD eGFR, mL/min as printed in this label Renal action or finding Belzutifan has no routine renal reduction, including in ESRD. At MDRD eGFR 15-29 mL/min, monitor closely for adverse reactions and adjust for toxicity. Limits and monitoring Use product-specific instructions for anemia, hypoxia and other toxicities. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 13, posted Oct 12, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Benralizumab clearance at CrCl 30-80 mL/min was comparable to that observed in patients with normal renal function. Limits and monitoring The quoted analysis supplies no dialysis regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 27, posted May 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
